CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
Transcu O2®device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03960463
NCT03960463N/ACompleted

Evaluation of Oxygen Delivery With TransCu O2 to Study Success Rate of Surgically Closed Wounds

Baylor College of Medicine·interventional·Posted May 23, 2019·Updated Jan 23, 2025

In Brief

A clinical study evaluating Transcu O2® for Surgical Wound and 6 related conditions. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The investigators will test the efficacy of the novel oxygen diffusion dressing allows delivery tissue oxygenation via TransCu O2® Oxygen Delivery System for use in caring for patients with surgically closed wounds. The investigators hypothesize that using this novel oxygen diffusion dressing will reduce the likelihood of necrotic tissue as well as severe incisional scar post-surgical closure by improving transcutaneous oxygen levels during wound healing process. TransCu O2 Oxygen Delivery System is a novel wound healing therapy that promises to enhance tissue hydration, which in turn may lead to quick epithelialization essential to reduce the likelihood of formation of necrotic tissue and excessive scars.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMay 23, 2019
Enrollment StartMay 18, 2017
Primary CompletionDec 15, 2023
Study CompletionJul 24, 2024
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 7.1 years ago

Interventions

Transcu O2®device

Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.